Penumbra Inc (PEN)
Gross profit margin
Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Gross profit (ttm) | US$ in thousands | 682,643 | 634,078 | 591,687 | 558,861 | 535,207 | 522,227 | 506,812 | 491,463 | 475,382 | 444,248 | 415,259 | 361,503 | 338,175 | 341,990 | 347,065 | 376,063 | 371,964 | 352,548 | 331,562 | 309,886 |
Revenue (ttm) | US$ in thousands | 1,058,522 | 995,059 | 937,791 | 884,636 | 847,133 | 829,928 | 806,367 | 782,281 | 747,590 | 710,477 | 671,436 | 592,287 | 560,412 | 538,777 | 527,203 | 556,295 | 547,405 | 522,935 | 495,239 | 470,676 |
Gross profit margin | 64.49% | 63.72% | 63.09% | 63.17% | 63.18% | 62.92% | 62.85% | 62.82% | 63.59% | 62.53% | 61.85% | 61.04% | 60.34% | 63.48% | 65.83% | 67.60% | 67.95% | 67.42% | 66.95% | 65.84% |
December 31, 2023 calculation
Gross profit margin = Gross profit (ttm) ÷ Revenue (ttm)
= $682,643K ÷ $1,058,522K
= 64.49%
Penumbra Inc's gross profit margin has shown a relatively stable trend over the past eight quarters, ranging from 62.82% to 64.49%. The company has maintained a healthy level of gross profit margin, indicating its ability to effectively manage production costs and generate profits from sales. This consistent performance suggests that Penumbra Inc has a strong pricing strategy and efficient cost controls in place. Overall, the company's gross profit margin reflects its operational efficiency and profitability in generating revenue after accounting for the cost of goods sold.
Peer comparison
Dec 31, 2023
Company name
Symbol
Gross profit margin
Penumbra Inc
PEN
64.49%
3M Company
MMM
43.46%
Artivion Inc
AORT
69.22%
Baxter International Inc
BAX
33.34%
Becton Dickinson and Company
BDX
5.19%
Boston Scientific Corp
BSX
70.82%
DexCom Inc
DXCM
63.52%
Embecta Corp
EMBC
66.89%
Glaukos Corp
GKOS
78.86%
Globus Medical
GMED
65.05%
Haemonetics Corporation
HAE
26.64%